Unknown

Dataset Information

0

Antiosteoporosis medications and cardiovascular disease: a population-based nationwide nested case-control study.


ABSTRACT: Purpose: Patients with osteoporosis are at an increased risk of cardiovascular disease (CVD). Several antiosteoporosis medications have been demonstrated with the benefit of preventing osteoporosis. Our aim is to assess the CVD risks associated with antiosteoporosis medications using the National Health Insurance Research Database in Taiwan between 2000 and 2016. Methods: Among 41,102 patients of 40+ years old with newly diagnosed osteoporosis, 69.1% (N = 28,387) of patients were included in the user cohort of antiosteoporosis medicines, of whom 13, 472 developed CVD by the end of 2016, while 14,915 did not. Using the nested case-control analysis in the user cohort (88.0% women and 77.4% elderly), we applied conditional logistic regression to estimate odds ratios (ORs) of eight types of CVD for the users of denosumab, bisphosphonate, teriparatide, and hormone replacement therapy (HRT). Results: The adjusted ORs of overall CVDs were 0.13 (95% CI: 0.12-0.15) for denosumab users, 0.52 (95% CI: 0.45-0.61) for teriparatide users, and 0.80 (95% CI: 0.76-0.85) for bisphosphonate users. The HRT users were at higher odds of coronary artery and peripheral artery diseases, heart failure, pulmonary embolism, and deep vein thrombosis. Conclusion: Denosumab, teriparatide, and bisphosphonate may have more protective effects against CVD than hormone therapy. Physicians may take subsequent cardiovascular risks into account when choosing an adequate antiosteoporosis medication for patients with osteoporosis.

SUBMITTER: Tsai WH 

PROVIDER: S-EPMC10595014 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

altmetric image

Publications

Antiosteoporosis medications and cardiovascular disease: a population-based nationwide nested case-control study.

Tsai Wen-Hsuan WH   Sung Fung-Chang FC   Muo Chih-Hsin CH   Tsai Ming-Chieh MC   Wu Shu-I SI  

Frontiers in pharmacology 20231010


<b>Purpose:</b> Patients with osteoporosis are at an increased risk of cardiovascular disease (CVD). Several antiosteoporosis medications have been demonstrated with the benefit of preventing osteoporosis. Our aim is to assess the CVD risks associated with antiosteoporosis medications using the National Health Insurance Research Database in Taiwan between 2000 and 2016. <b>Methods:</b> Among 41,102 patients of 40+ years old with newly diagnosed osteoporosis, 69.1% (N = 28,387) of patients were i  ...[more]

Similar Datasets

| S-EPMC9986836 | biostudies-literature
| S-EPMC5988075 | biostudies-literature
| S-EPMC6452576 | biostudies-literature
| S-EPMC7217430 | biostudies-literature
| S-EPMC9902356 | biostudies-literature
| S-EPMC8814784 | biostudies-literature
| S-EPMC3784020 | biostudies-literature
| S-EPMC4905503 | biostudies-literature
| S-EPMC10302215 | biostudies-literature
| S-EPMC3324433 | biostudies-literature